Advertisement
Screener

IDEXX LABORATORIES INC /DE (IDXX) Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent

3.5 / 5 stars · 83/120 Roast Me

IDEXX LABORATORIES INC /DE Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent

IDEXX LABORATORIES INC /DE (IDXX) reported Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent of -$25.00 thousand for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-03.

Financial Statements › Income Statement › Unrealized Gains

us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent · last filed 2025-11-03

  • IDEXX LABORATORIES INC /DE other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax, attributable to parent for the quarter ending 2025-09-30 was -$25.00K.
  • IDEXX LABORATORIES INC /DE other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax, attributable to parent for the quarter ending 2025-06-30 was -$24.00K.
  • IDEXX LABORATORIES INC /DE other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax, attributable to parent for the quarter ending 2025-03-31 was -$22.00K.
  • IDEXX LABORATORIES INC /DE other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax, attributable to parent for the quarter ending 2024-09-30 was -$21.00K.
Period endOther Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent 3 monthOther Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent 6 monthOther Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent 9 month
2025-09-30-$25.00K
10-Q · filed 2025-11-03
-$49.00K
derived: sum of 2 quarters · filed 2025-11-03
-$71.00K
10-Q · filed 2025-11-03
2025-06-30-$24.00K
10-Q · filed 2025-08-04
-$46.00K
10-Q · filed 2025-08-04
2025-03-31-$22.00K
10-Q · filed 2025-05-01
2024-09-30-$21.00K
10-Q · filed 2025-11-03
-$31.00K
derived: sum of 2 quarters · filed 2025-11-03
-$50.00K
10-Q · filed 2025-11-03
2024-06-30-$10.00K
10-Q · filed 2025-08-04
-$29.00K
10-Q · filed 2025-08-04
2024-03-31-$19.00K
10-Q · filed 2025-05-01
2023-09-30-$21.00K
10-Q · filed 2024-10-31
-$55.00K
derived: sum of 2 quarters · filed 2024-10-31
-$75.00K
10-Q · filed 2024-10-31
2023-06-30-$34.00K
10-Q · filed 2024-08-06
-$54.00K
10-Q · filed 2024-08-06
2023-03-31-$20.00K
10-Q · filed 2024-05-01

Similar stocks

Stock NameCountryMarket CapPE Ratio
Lantheus Holdings, Inc. (LNTH)United States$6.510B26.31
NEOGEN CORP (NEOG)United States$2.979B-247.49
Celldex Therapeutics, Inc. (CLDX)United States$2.471B-9.72
Intellia Therapeutics, Inc. (NTLA)United States$1.705B-5.92
ACHIEVE LIFE SCIENCES, INC. (ACHV)United States$0.806B-5.88
QuidelOrtho Corp (QDEL)United States$0.733B-0.90
Alpha Teknova, Inc. (TKNO)United States$0.500B-18.12
MYRIAD GENETICS INC (MYGN)United States$0.397B-4.84
Insight Molecular Diagnostics Inc. (IMDX)United States$0.129B-3.90
IMMUCELL CORP /DE/ (ICCC)United States$0.091B116.10